pharmaphorum

JANUARY 10, 2022

Not only this, the potential for this type of therapy extends far beyond infectious diseases and into numerous therapy areas. On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. Attracting attention.

RNA 111

RNA Vaccine Vaccination Pharma Companies 111

XTalks

DECEMBER 22, 2021

The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. To develop these novel RNA-based therapeutics, we saw a number of big pharma companies team up with smaller biotechs focused on developing RNA-based therapeutics.

Life Science 98

Life Science RNA Vaccine Vaccination 98

XTalks

DECEMBER 29, 2022

In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. Given their precise targeting, gene therapies have largely been focused on oncology indications followed by rare genetic diseases.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

JANUARY 6, 2025

RNA-based therapies hold the potential to offer new treatment options for diseases with limited or inadequate therapeutic alternatives. Gene Editing CRISPR-Cas9 and related gene-editing technologies continue to advance, and today they are widely used to study and develop therapeutic approaches for a broad range of human diseases.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111